Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Stock Short Interest Report for October

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 15,751 shares, a decline of 38.8% from the September 30th total of 25,736 shares. Based on an average trading volume of 26,150 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.9% of the company’s shares are sold short.

Bolt Biotherapeutics Stock Down 5.3%

NASDAQ:BOLT opened at $6.24 on Tuesday. Bolt Biotherapeutics has a fifty-two week low of $3.10 and a fifty-two week high of $7.78. The firm has a market cap of $12.04 million, a P/E ratio of -0.38 and a beta of 1.00. The firm has a 50-day simple moving average of $4.19 and a two-hundred day simple moving average of $4.52. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Tuesday, August 11th. The company reported ($4.57) EPS for the quarter, missing the consensus estimate of ($3.39) by ($1.18). Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.50 million. Analysts predict that Bolt Biotherapeutics will post -11.10 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $14.50.

Insider Activity

In related news, CEO William Quinn sold 9,132 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $3.24, for a total transaction of $29,587.68. Following the transaction, the chief executive officer owned 25,384 shares in the company, valued at $82,244.16. The trade was a 26.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 38,584 shares of company stock valued at $128,361 over the last quarter. 9.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bolt Biotherapeutics

An institutional investor recently bought a new stake in Bolt Biotherapeutics stock. Nan Fung Group Holdings Ltd bought a new stake in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 5,000 shares of the company’s stock, valued at approximately $19,250. Bolt Biotherapeutics comprises approximately 0.0% of Nan Fung Group Holdings Ltd’s holdings, making the stock its 25th largest position. Nan Fung Group Holdings Ltd owned about 0.26% of Bolt Biotherapeutics at the end of the most recent quarter. 86.70% of the stock is currently owned by institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment.

Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.